Context
Lysogene is a leading biotechnology company specialized in the development of AAV-based gene therapies with a portfolio of candidates to treat rare central nervous system diseases.
Lead candidate LYS-SAF302 is indicated for the treatment of MPSIIIA (Sanfilippo Syndrome), a rare lysosomal storage disease for which there is no treatment. This disease affects children who suffer from impaired cognitive and motor functions and have short life expectancy.
Lysogene has already obtained efficacy signals in a Phase I/II study and is finalizing the recruitment of the pivotal Phase II/III trial for LYS-SAF302, which has the potential to become first- and best-in-class.
Proceeds will primarily be used to finance the Phase I/III trial of LYS-GM101 in GM1 gangliosidosis and the preparation of LYS-SAF302’s commercial launch in Europe for MPSIIIA.
About Lysogene
Lysogene is a gene therapy company focused on the treatment of orphan diseases of the central nervous system (CNS). The company has built a unique capability to enable a safe and effective delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. is ongoing and a phase 1/3 clinical trial in GM1 gangliosidosis is in preparation. In accordance with the agreements signed between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial rights to LYS-SAF302 in the United States and markets outside Europe; and Lysogene will maintain commercial exclusivity of LYS-SAF302 in Europe. Lysogene is also collaborating with an academic partner to define the strategy of development for the treatment of Fragile X syndrome, a genetic disease related to autism.
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acts as Sole Global Coordinator and Sole Bookrunner on Lysogene’s Private Placement with top tier US and European Investors
Bryan, Garnier & Co acted as Sole Global Coordinator and Sole Bookrunner on the 11 March 2020 for the EUR 7.7m Private Placement, which closed on 18 March.
In a wall-crossed overnight ABB, Lysogene raised EUR 7.7m from Tier-1 US and European healthcare specialists, including OrbiMed Advisors LLC. Sarepta Therapeutics, company’s key shareholder and partner for its MPS IIIA clinical trial also participated in the Offering.
The raise was priced at EUR 2.83 per share, representing a discount of 5.8% over the 10-day VWAP of Lysogene on 11 March 2020 despite the current complex and strained funding environment.
This transaction further underscores Bryan, Garnier & Co’s ability to raise capital for European biotech despite complex fundraising environment.
Share